Role of STAT3 Signaling Pathway in Breast Cancer

Overview

Journal Cell Commun Signal

Publisher Biomed Central

Specialties Biochemistry
Cell Biology

Date 2020 Mar 1

PMID 32111215

Citations 149

Authors

Jia-Hui Ma

Li Qin

Xia Li

Affiliations

Soon will be listed here.

Abstract

Breast cancer has grown to be the second leading cause of cancer-related deaths in women. Only a few treatment options are available for breast cancer due to the widespread occurrence of chemoresistance, which emphasizes the need to discover and develop new methods to treat this disease. Signal transducer and activator of transcription 3 (STAT3) is an early tumor diagnostic marker and is known to promote breast cancer malignancy. Recent clinical and preclinical data indicate the involvement of overexpressed and constitutively activated STAT3 in the progression, proliferation, metastasis and chemoresistance of breast cancer. Moreover, new pathways comprised of upstream regulators and downstream targets of STAT3 have been discovered. In addition, small molecule inhibitors targeting STAT3 activation have been found to be efficient for therapeutic treatment of breast cancer. This systematic review discusses the advances in the discovery of the STAT3 pathways and drugs targeting STAT3 in breast cancer. Video abstract.

Citing Articles

A combinatorial screening protocol for identifying novel and highly potent dual-target inhibitor of BRD4 and STAT3 for kidney cancer therapy.

Zhang S, Wu N, Geng Y, Guan L, Niu M, Li J Front Pharmacol. 2025; 16:1560559.

PMID: 40078291 PMC: 11897524. DOI: 10.3389/fphar.2025.1560559.

Targeting STAT3 for Cancer Therapy: Focusing on Y705, S727, or Dual Inhibition?.

Berkley K, Zalejski J, Sharma A Cancers (Basel). 2025; 17(5).

PMID: 40075607 PMC: 11898704. DOI: 10.3390/cancers17050755.

Reversal of chemotherapy resistance in gastric cancer with traditional Chinese medicine as sensitizer: potential mechanism of action.

Zhou C, Wu K, Gu M, Yang Y, Tu J, Huang X Front Oncol. 2025; 15:1524182.

PMID: 40052129 PMC: 11882405. DOI: 10.3389/fonc.2025.1524182.

Enhancement of radio-sensitivity by inhibition of Janus kinase signaling with oclacitinib in canine tumor cell lines.

Owaki R, Hosoya K, Deguchi T, Konnai S, Maekawa N, Okagawa T Mol Ther Oncol. 2025; 33(1):200946.

PMID: 40051504 PMC: 11883359. DOI: 10.1016/j.omton.2025.200946.

Roles of Post-Translational Modifications of Transcription Factors Involved in Breast Cancer Hypoxia.

Seymour L, Nuru N, Johnson K, Gutierrez J, Njoku V, Darie C Molecules. 2025; 30(3).

PMID: 39942749 PMC: 11820228. DOI: 10.3390/molecules30030645.

References

Zeng A, Yu Y, Yao Y, Yang F, Liao M, Song L . Betulinic acid impairs metastasis and reduces immunosuppressive cells in breast cancer models. Oncotarget. 2018; 9(3):3794-3804. PMC: 5790500. DOI: 10.18632/oncotarget.23376. View

Yu H, Lee H, Herrmann A, Buettner R, Jove R . Revisiting STAT3 signalling in cancer: new and unexpected biological functions. Nat Rev Cancer. 2014; 14(11):736-46. DOI: 10.1038/nrc3818. View

Kettner N, Vijayaraghavan S, Guray Durak M, Bui T, Kohansal M, Ha M . Combined Inhibition of STAT3 and DNA Repair in Palbociclib-Resistant ER-Positive Breast Cancer. Clin Cancer Res. 2019; 25(13):3996-4013. PMC: 6606366. DOI: 10.1158/1078-0432.CCR-18-3274. View

Cheng C, Shi L, Wang X, Wang S, Wan X, Liu S . Stat3/Oct-4/c-Myc signal circuit for regulating stemness-mediated doxorubicin resistance of triple-negative breast cancer cells and inhibitory effects of WP1066. Int J Oncol. 2018; 53(1):339-348. DOI: 10.3892/ijo.2018.4399. View

Oh E, Kim Y, An H, Sung D, Cho T, Farrand L . Flubendazole elicits anti-metastatic effects in triple-negative breast cancer via STAT3 inhibition. Int J Cancer. 2018; 143(8):1978-1993. DOI: 10.1002/ijc.31585. View

Wang W, Hayashi J, Serrero G . PC cell-derived growth factor confers resistance to dexamethasone and promotes tumorigenesis in human multiple myeloma. Clin Cancer Res. 2006; 12(1):49-56. DOI: 10.1158/1078-0432.CCR-05-0929. View

Levy D, Lee C . What does Stat3 do?. J Clin Invest. 2002; 109(9):1143-8. PMC: 150972. DOI: 10.1172/JCI15650. View

Chen W, Wang H, Cheng M, Ni L, Zou L, Yang Q . Isoharringtonine inhibits breast cancer stem-like properties and STAT3 signaling. Biomed Pharmacother. 2018; 103:435-442. DOI: 10.1016/j.biopha.2018.04.076. View

Tzeng Y, Liu P, Li J, Liu L, Kuo S, Hsieh C . Kinome-Wide siRNA Screening Identifies Src-Enhanced Resistance of Chemotherapeutic Drugs in Triple-Negative Breast Cancer Cells. Front Pharmacol. 2018; 9:1285. PMC: 6238227. DOI: 10.3389/fphar.2018.01285. View

10.

Hosea R, Silvia Hardiany N, Ohneda O, Wanandi S . Glucosamine decreases the stemness of human ALDH breast cancer stem cells by inactivating STAT3. Oncol Lett. 2018; 16(4):4737-4744. PMC: 6126220. DOI: 10.3892/ol.2018.9222. View

11.

Soleymani Abyaneh H, Gupta N, Alshareef A, Gopal K, Lavasanifar A, Lai R . Hypoxia Induces the Acquisition of Cancer Stem-like Phenotype Via Upregulation and Activation of Signal Transducer and Activator of Transcription-3 (STAT3) in MDA-MB-231, a Triple Negative Breast Cancer Cell Line. Cancer Microenviron. 2018; 11(2-3):141-152. PMC: 6250616. DOI: 10.1007/s12307-018-0218-0. View

12.

Mitsuyama K, Matsumoto S, Masuda J, Yamasakii H, Kuwaki K, Takedatsu H . Therapeutic strategies for targeting the IL-6/STAT3 cytokine signaling pathway in inflammatory bowel disease. Anticancer Res. 2007; 27(6A):3749-56. View

13.

Wang L, Shi H, Zhang X, Zhang X, Liu Y, Kang W . I157172, a novel inhibitor of cystathionine γ-lyase, inhibits growth and migration of breast cancer cells via SIRT1-mediated deacetylation of STAT3. Oncol Rep. 2018; 41(1):427-436. DOI: 10.3892/or.2018.6798. View

14.

Pang Y, Wu J, Li X, Wang C, Wang M, Liu J . NEAT1/miR‑124/STAT3 feedback loop promotes breast cancer progression. Int J Oncol. 2019; 55(3):745-754. DOI: 10.3892/ijo.2019.4841. View

15.

Pham T, Bak Y, Kwon T, Kwon S, Oh J, Park J . Interleukin-32θ inhibits tumor-promoting effects of macrophage-secreted CCL18 in breast cancer. Cell Commun Signal. 2019; 17(1):53. PMC: 6534939. DOI: 10.1186/s12964-019-0374-y. View

16.

Hata T, Rajabi H, Yamamoto M, Jin C, Ahmad R, Zhang Y . Targeting MUC1-C Inhibits TWIST1 Signaling in Triple-Negative Breast Cancer. Mol Cancer Ther. 2019; 18(10):1744-1754. PMC: 6774902. DOI: 10.1158/1535-7163.MCT-19-0156. View

17.

Valeta-Magara A, Gadi A, Volta V, Walters B, Arju R, Giashuddin S . Inflammatory Breast Cancer Promotes Development of M2 Tumor-Associated Macrophages and Cancer Mesenchymal Cells through a Complex Chemokine Network. Cancer Res. 2019; 79(13):3360-3371. PMC: 7331114. DOI: 10.1158/0008-5472.CAN-17-2158. View

18.

Locken H, Clamor C, Muller K . Napabucasin and Related Heterocycle-Fused Naphthoquinones as STAT3 Inhibitors with Antiproliferative Activity against Cancer Cells. J Nat Prod. 2018; 81(7):1636-1644. DOI: 10.1021/acs.jnatprod.8b00247. View

19.

Shi P, Chen C, Li X, Wei Z, Liu Z, Liu Y . MicroRNA‑124 suppresses cell proliferation and invasion of triple negative breast cancer cells by targeting STAT3. Mol Med Rep. 2019; 19(5):3667-3675. PMC: 6472193. DOI: 10.3892/mmr.2019.10044. View

20.

Egusquiaguirre S, Yeh J, Walker S, Liu S, Frank D . The STAT3 Target Gene TNFRSF1A Modulates the NF-κB Pathway in Breast Cancer Cells. Neoplasia. 2018; 20(5):489-498. PMC: 5916089. DOI: 10.1016/j.neo.2018.03.004. View